Literature DB >> 6572735

Establishment of a Ph1-positive human cell line (BV173).

L Pegoraro, L Matera, J Ritz, A Levis, A Palumbo, G Biagini.   

Abstract

A new cell line (BV173) derived from a patient with Philadelphia chromosome (Ph1)-positive acute leukemia was compared with the Ph1-positive K562 and NALM-1 lines, which display the phenotypic characteristics of erythroid and pre-B cells, respectively. BV173 cells retained the Ph1 chromosome and had the morphologic and cytochemical features of undifferentiated blast cells. They lacked the membrane characteristics of mature B- or T-lymphocytes and did not react with monoclonal antibodies to the myelomonocytic cell lineage. Although they reacted with anti-glycophorin A antiserum, they failed to produce hemoglobin after butyric acid treatment. This line was similar to NALM-1 in that it bore common acute lymphoblastic leukemia antigen and la-like antigen, reacted with monoclonal antibodies directed against early stages of hematopoietic cell differentiation, and presented the nuclear enzyme terminal deoxynucleotidyl transferase. However, it differed from NALM-1 because it did not express cytoplasmic IgM, a marker of pre-B-cells. The new line can be considered a clonal expansion of leukemia cells blocked at an earlier differentiation stage than that for the other Ph1-positive cell lines.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6572735

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  45 in total

1.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.

Authors:  S Ziemin-van der Poel; N R McCabe; H J Gill; R Espinosa; Y Patel; A Harden; P Rubinelli; S D Smith; M M LeBeau; J D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.

Authors:  Silvia Fernández de Mattos; Abdelkader Essafi; Inês Soeiro; Alexandra M Pietersen; Kim U Birkenkamp; Corinne S Edwards; Anthony Martino; Brad H Nelson; Julia M Francis; Marius C Jones; Jan J Brosens; Paul J Coffer; Eric W-F Lam
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

3.  Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines.

Authors:  H M Pomykala; S K Bohlander; P L Broeker; O I Olopade; M O Díaz
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

4.  Interactions of the transcription factors MIBP1 and RFX1 with the EP element of the hepatitis B virus enhancer.

Authors:  M Blake; J Niklinski; M Zajac-Kaye
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

5.  Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Valentina Minieri; Marco De Dominici; Patrizia Porazzi; Samanta A Mariani; Orietta Spinelli; Alessandro Rambaldi; Luke F Peterson; Pierluigi Porcu; Marja T Nevalainen; Bruno Calabretta
Journal:  Cancer Res       Date:  2018-08-28       Impact factor: 12.701

6.  Insulin requirement of human leukemic cell lines.

Authors:  G Garbarino; G L Pagliardi; A Palumbo; G Turco; L Pegoraro
Journal:  Experientia       Date:  1985-08-15

7.  Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.

Authors:  T Skorski; M Nieborowska-Skorska; N C Nicolaides; C Szczylik; P Iversen; R V Iozzo; G Zon; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

8.  Adipocytes impair leukemia treatment in mice.

Authors:  James W Behan; Jason P Yun; Marina P Proektor; Ehsan A Ehsanipour; Anna Arutyunyan; Ara S Moses; Vassilios I Avramis; Stan G Louie; Anna Butturini; Nora Heisterkamp; Steven D Mittelman
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

9.  Changes in tyrosine-phosphorylated p190 and its association with p120 type I and p100 type II rasGAPs during myelomonocytic differentiation of human leukemic cells.

Authors:  J C Cheng; A R Frackelton; E L Bearer; P S Kumar; B Kannan; A Santos-Moore; A Rifai; J Settleman; J W Clark
Journal:  Cell Growth Differ       Date:  1995-02

10.  Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.

Authors:  T Skorski; M Nieborowska-Skorska; C Barletta; L Malaguarnera; C Szcyzlik; S T Chen; B Lange; B Calabretta
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.